Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

9.305 +0.225 (+2.48%)
Streaming Delayed Price Updated: 10:23 AM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics's Return On Capital Employed Overview
Bicycle Therapeutics (NASDAQ:BCYC) brought in sales totaling $3.77 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 22.88%, resulting in a... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Bicycle Therapeutics
Analysts have provided the following ratings for Bicycle Therapeutics (NASDAQ:BCYC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Bicycle Therapeutics: Q4 Earnings Insights
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,... 
Via Benzinga
Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
From Bicycle Therapeutics plc
Via Business Wire
Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength
The list features stocks from diverse sectors as the economy recovers from the pandemic. 
Via Investor's Business Daily
7 A-Rated Biotechs to Buy for the Long Run
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples. 
Via InvestorPlace
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Looking Into Bicycle Therapeutics's Return On Capital Employed
According to Benzinga Pro data, during Q3, Bicycle Therapeutics (NASDAQ:BCYC) posted sales of $4.33 million. Earnings were up 17.27%, but Bicycle Therapeutics still reported an... 
Via Benzinga
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal for ImmunoTherapy of Cancer
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares
From Bicycle Therapeutics plc
Via Business Wire
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares
From Bicycle Therapeutics plc
Via Business Wire
45 Biggest Movers From Yesterday
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial... 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial
Bicycle Therapeutics plc (NASDAQ: BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escalation portion of... 
Via Benzinga
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
From Bicycle Therapeutics plc
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular session. Voyager Therapeutics's stock is trading at a... 
Via Benzinga
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.